A Study On The İnteraction of Aspirin and Some Effective Compounds with Covid-19, Prostaglandins and Thromboxane Receptors

Abstract

In the studies of Hippocrates, it was stated that the leaves of the willow tree were used as a painkiller. In the discovery of salicylic acid, it was converted into acetylsalicylic acid and used as aspirin. In this study, the inhibitory effect of aspirin, which is effective in many diseases, on the mechanism of action on Covid-19 has been investigated. In addition, the interaction of prostaglandins and thromboxane, which increased in amount with this virus, with other effective compounds (Pitavastatin, Rosoxacin, Ridogrel) has tried to be determined comparatively. In addition to the effect of aspirin on this virus, many diagnostic and treatment methods have been developed in its treatment and it is known to be effective on diseases whose mortality is a serious health problem. Chemical calculation method has been used to clarify, understand and examine the interactions of the metabolic events mentioned here. Recently, scientists have been studying on targeted treatments. A drug that will be formed from an active molecule to be developed for the target will provide more effective results by suppressing the proliferation, growth and spread of the target unit.

Keywords

• thromboxane
• Aspirin
• pitavastatin
• rosoxacin
• ridogrel
• prostaglandins
• thromboxane
• SARS-CoV-2

References

1. 1. Merzon, E.; Green, I.; Vinker, S. ; Golan-Cohen, A., ; Gorohovski, E.; Avramovich, M.; Frenkel-Morgenstern, E.; Magen, FEBS J. 2021.
2. 2.Yaqian, F. ; Lei, T. ; Guoqiang, W. ; Zhen, L. ; Mingming, Y. ; Weishen, H. ; Xincheng, Z.; Yong, Z. ; Jinliang, Y. ; Shinghu, C. ; Fiona, M. ; Ligong, C., European Journal of Pharmacology, 2021, 906 , 174173.
3. 3.Kathleen, M.; Buchheit, Katherine N.; Cahill, Howard R.; Katz, Katherine C.; Murphy, Chunli Feng, Kathleen Lee-Sarwar, Juying Lai, Neil Bhattacharyya, Elliot I.; Joshua A.; Boyce, Tanya M. L., Journal of Allergy and Clinical Immunology, 2016,137, 5, 1566-1576.e5.
4. 4.Undas, A. ; Kathleen E.; Brummel-Ziedins, Kenneth G.; Mann, Blood, 2007,109 -6 (2007) 2285–2292.
5. 5.Roth, GJ.; Calverley, DC., Blood, 1994, 83, 885-98.
6. 6.Taddei, C.; Morse, CL. ; Kim, MJ. ; Liow, J-S. ; Santamaria, JM. ; Zhang, A. ; Manly, LS. ; Zanotti-Fregonara, P.; Gladding, RL. ; Zoghbi, SS. ; Innis, RB. ; Pike, VW. ; ACS Chemical Neuroscience, 2021,12-3, 517-530.
7. 7.Xi, Y.; Qin, Z. ; Yan, A., SAR and QSAR in Environmental Research, 2018,29:10, 755-784.
8. 8.Yang, W.; Xiong, G.; Lin, B., J Neuroinflammation, 2020, 17,306 https://doi.org/10.1186/s12974-020-01993-0.

9. 9.Kamo, M.; Furubayashi, N.; Inaka, K.; Aritake, K.; Urade, Y., Crystal structure of hematopoietic prostaglandin D synthase apo form,2018 ,Doi: 10.2210/pdb5ywe/pdb.
10. 10.Fan, H. ; Zhao, Q. ; Wu, B., Crystal structure of the human thromboxane A2 receptor bound to ramatroban, 2018, Doi: 10.2210/pdb6IIU/pdb.
11. 11.Fan, H.; Chen, S.; Yuan, X.; Han, S.; Zhang, H.; Xia, W.; Xu, Y.; Zhao, Q.; Wu, B., Nat Chem Biol.,2019, 15, 27-33.
12. 12.Abosheasha, MA.; El-Gowily, AH., Drug Dev Res. 2021, 82, 217– 229.
13. 13.Bondhon, TA., Rana, MAH.; Hasan, A. ; Jahan, R. ; Jannat, K.; Rahmatullah, M., Asian Journal of Research in Infectious Diseases,2020, 4-4,8-14.
14. 14.Abosheasha, MA.; El-Gowily, AH.; Elfiky, AA., J Thromb Thrombolysis, 2021,
15. 15.Walls, AC.; Park, YJ.; Tortorici, MA.; Wall, A., Seattle Structural Genomics Center for Infectious Disease (SSGCID), McGuire, A.T., Veesler, D., SARS-CoV-2 spike ectodomain structure (open state) ,2020, doi: 10.2210/pdb6VYB/pdb.
16. 16.Walls, AC. ; Park, YJ.; Tortorici, MA. ; Wall, A. ; McGuire, A.T. ; Veesler, D., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cell,2020, 16;181-2, 281-292.e6.
17. 17.Pedro Souza, FN. ; Francisco Lopes, ES. ; Jackson Amaral, L ; Cleverson Freitas, DT. ; Jose T.A; Oliveira, International Journal of Biological Macromolecules,2020, 164, 66-76,ISSN 0141-8130.
18. 18.Khairan, K. ; Idroes, R.; Tumilaar, SG .; Tallei, T E. ; Idroes, G M. ; Rahmadhany,F. Futri, MU.; Dinura, NM.; Mauliza, S.; Diana,M.; Maisarah, CP.; Maulana, A.;Noviandy, TR.; Suhendra, R.; Muslem, N Earlia , IOP Conference Series: IOP Conf. Ser.: Mater. Sci. Eng. 2021, 1087 012058.
19. 19.Baby, K. ; Maity, S.; Mehta, CH.; Suresh, A.; Nayak, UY.; Nayak, Y., F1000Res., 2020, 23;9, 1166. doi: 10.12688/f1000research.26359.1.
20. 20.Tallei, TE. ; Maulana, RR.; Windah, ALL.; Wahongan, IF. ; Tumilaar, SG.; Fatimawali, M. ; Kumaunang, A M Sambul, A A Adam, R Idroes, IOP Conf. Ser.: Earth Environ. Sci.2021, 667, 012034.
21. 21.Singh, G.; Fauzi, N.; Fauzi, N. B., A Review.Cureus,2023,15(7).
22. 22.Chiang, K. C.; Gupta, A.; Sundd, P.; Krishnamurti, L., Biomedicines, 2023,11(2), 338.
23. 23.Arockiam, S.; Staniforth, B.; Kepreotis, S.; Maznyczka, A.; Bulluck, H., International Journal of Molecular Sciences, 2023,24(13), 11132.
24. 24.Afroze, S.; Janakiraman, A. K.; Gunasekaran, B.; Djearamane, S.; Wong, L. S., Journal of Pharmacy & Pharmacognosy Research,2024, 12(1), 120-145.
25. 25.Singh, S.; Sharma, K.; Sharma, H., Current Drug Delivery,2024; 21(4), 544-570.
26. 26.Warner, T. D.; Nylander, S.; Whatling, C., British journal of clinical pharmacology,2011; 72(4), 619‐633.
27. 27.Ritter, J. M.; Cockcroft, J. R.; Doktor, H. S.; Beacham, J.; Barrow, S. E., British journal of clinical pharmacology,1989, 28(5), 573‐579.
28. 28.Osborne, T. F.; Veigulis, Z. P.; Arreola, D. M.; Mahajan, S. M.; Röösli, E.; Curtin, C. M.; PloS one, 2021,16(2), e0246825.
29. 29.Paidi, R. K.; Jana, M.; Mishra, R. K.; Dutta, D.; Raha, S.; Pahan, K., Journal of Neuroimmune Pharmacology,2021, 16, 59-70.
30. 30.Archambault, A. S.; Zaid, Y.; Rakotoarivelo, V.; Turcotte, C.; Doré, É., Dubuc, I., ... & Flamand, N., The FASEB journal, 2021, 35(6).
31. 31.Satapathy, S. K.; Singh, S. P.; Anirvan, P., In Hepatology (pp. 1349-1383).,2025, Academic Press.
32. 32.Zhang, J.; Chen, C.; Yan, W.; Fu, Y., Frontiers in Pharmacology,2024, 14, 1303913.
33. 33.Cheng, X.; Zhao, F.; Ke, B.; Chen, D.; Liu, F., Cancers, 2023,15(21), 5209.